CN110959002A - 脂化肽的水溶性盐、其制备方法及用途 - Google Patents

脂化肽的水溶性盐、其制备方法及用途 Download PDF

Info

Publication number
CN110959002A
CN110959002A CN201980003752.4A CN201980003752A CN110959002A CN 110959002 A CN110959002 A CN 110959002A CN 201980003752 A CN201980003752 A CN 201980003752A CN 110959002 A CN110959002 A CN 110959002A
Authority
CN
China
Prior art keywords
compound
acid
formula
mixture
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980003752.4A
Other languages
English (en)
Chinese (zh)
Inventor
姜相旭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bilgi Biotechnology Co ltd
Original Assignee
Bilgi Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bilgi Biotechnology Co ltd filed Critical Bilgi Biotechnology Co ltd
Publication of CN110959002A publication Critical patent/CN110959002A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
CN201980003752.4A 2018-02-28 2019-02-27 脂化肽的水溶性盐、其制备方法及用途 Pending CN110959002A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636552P 2018-02-28 2018-02-28
US62/636,552 2018-02-28
PCT/KR2019/002397 WO2019168357A1 (en) 2018-02-28 2019-02-27 Water soluble salts of lipidated peptides and methods for preparing and using the same

Publications (1)

Publication Number Publication Date
CN110959002A true CN110959002A (zh) 2020-04-03

Family

ID=67684306

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980003752.4A Pending CN110959002A (zh) 2018-02-28 2019-02-27 脂化肽的水溶性盐、其制备方法及用途

Country Status (10)

Country Link
US (1) US11739120B2 (enExample)
EP (1) EP3759070A4 (enExample)
JP (2) JP7104141B2 (enExample)
KR (1) KR102058853B1 (enExample)
CN (1) CN110959002A (enExample)
MY (1) MY200470A (enExample)
PH (1) PH12020551233A1 (enExample)
SG (1) SG11202007544RA (enExample)
TW (2) TWI762770B (enExample)
WO (1) WO2019168357A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555106A (zh) * 2019-08-23 2022-05-27 毕利吉生物科技股份有限公司 包含棕榈酰-l-脯氨酰-l-脯氨酰-甘氨酰-l-酪氨酸钠的药物制剂及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111297905B (zh) * 2020-03-18 2022-11-04 四川大学华西医院 一种基于皮肤前体细胞的提取物及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4471115A (en) * 1980-10-13 1984-09-11 Neopharmed S.P.A. Water soluble derivatives of cephalex and process for their preparation
WO2010059922A1 (en) * 2008-11-21 2010-05-27 Ligand Pharmaceuticals Incorporated Pyrrolidine carboxamide compounds
WO2013190497A2 (en) * 2012-06-21 2013-12-27 Radikal Therapeutics Inc. Compositions and methods for treatment of inflammatory diseases of the lung
CN103724204A (zh) * 2013-11-27 2014-04-16 北京化工大学 一种水溶性引发剂及制备
CN107531753A (zh) * 2015-07-08 2018-01-02 成均馆大学校产学协力团 吡咯烷酰胺衍生物及其制备和使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3839127A1 (de) 1988-11-19 1990-05-23 Hoechst Ag Pyrrolidon-2-carbonsaeure-derivate mit psychotroper wirkung
AUPM906594A0 (en) 1994-10-26 1994-11-17 Peptide Technology Limited Synthetic polyunsaturated fatty acid analogues
GEP20002187B (en) 1996-05-01 2000-07-25 Ortho Pharma Corp Carboxamide Derivatives of Pyrrolidine, Piperidine and Hexahydroazepine, Composition for the Treatment of Thrombosis Disorders Induced by Thrombocytes, Intermediate Compounds and Method for Their Preparation
DE69915004T2 (de) 1998-11-05 2004-09-09 Pfizer Products Inc., Groton 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
WO2003007876A2 (en) 2001-06-25 2003-01-30 University Of Massachusetts N-fatty acid-amino acid conjugates and therapeutic uses
US20060252698A1 (en) 2005-04-20 2006-11-09 Malcolm Bruce A Compounds for inhibiting cathepsin activity
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
MX2010002300A (es) * 2007-08-29 2010-03-18 Pfizer Prod Inc Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos.
KR101151878B1 (ko) 2010-06-08 2012-05-31 미원상사주식회사 지방산 트리펩타이드염 및 이를 함유하는 항균 조성물
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
KR20120048864A (ko) 2010-11-08 2012-05-16 주식회사 네오디엠 트리 펩타이드 유도체를 함유한 아토피 피부염 예방 및 치료용 조성물과 그 제조방법
KR20130038426A (ko) 2011-10-07 2013-04-18 성균관대학교산학협력단 지방산이 결합된 항당뇨 펩티드가 소수성 결합된 글리콜 키토산 히드로겔 및 이를 포함하는 당뇨병 예방 또는 치료용 약학적 조성물
KR101359886B1 (ko) 2011-12-28 2014-02-12 성균관대학교산학협력단 스매드 6번(Ｓｍａｄ６)으로부터 유래된 펩타이드를 유효성분으로 포함하는 패혈증 또는 패혈성 쇼크의 치료용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4471115A (en) * 1980-10-13 1984-09-11 Neopharmed S.P.A. Water soluble derivatives of cephalex and process for their preparation
WO2010059922A1 (en) * 2008-11-21 2010-05-27 Ligand Pharmaceuticals Incorporated Pyrrolidine carboxamide compounds
WO2013190497A2 (en) * 2012-06-21 2013-12-27 Radikal Therapeutics Inc. Compositions and methods for treatment of inflammatory diseases of the lung
CN103724204A (zh) * 2013-11-27 2014-04-16 北京化工大学 一种水溶性引发剂及制备
CN107531753A (zh) * 2015-07-08 2018-01-02 成均馆大学校产学协力团 吡咯烷酰胺衍生物及其制备和使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555106A (zh) * 2019-08-23 2022-05-27 毕利吉生物科技股份有限公司 包含棕榈酰-l-脯氨酰-l-脯氨酰-甘氨酰-l-酪氨酸钠的药物制剂及其制备方法
CN114555106B (zh) * 2019-08-23 2024-09-20 毕利吉生物科技股份有限公司 包含棕榈酰-l-脯氨酰-l-脯氨酰-甘氨酰-l-酪氨酸钠的药物制剂及其制备方法

Also Published As

Publication number Publication date
KR20190103986A (ko) 2019-09-05
SG11202007544RA (en) 2020-09-29
TWI762770B (zh) 2022-05-01
WO2019168357A1 (en) 2019-09-06
JP2022106788A (ja) 2022-07-20
KR102058853B1 (ko) 2019-12-24
TW201936577A (zh) 2019-09-16
TWI811767B (zh) 2023-08-11
EP3759070A4 (en) 2021-12-08
JP7104141B2 (ja) 2022-07-20
US11739120B2 (en) 2023-08-29
PH12020551233A1 (en) 2021-05-17
TW202222818A (zh) 2022-06-16
JP2020529435A (ja) 2020-10-08
US20190263859A1 (en) 2019-08-29
EP3759070A1 (en) 2021-01-06
MY200470A (en) 2023-12-27

Similar Documents

Publication Publication Date Title
CN105143194B (zh) 依洛昔巴特的结晶修饰物
CN105848718B (zh) Aramchol盐
WO2022258060A1 (zh) 一种lanifibranor的晶型及其制备方法
WO2014127735A1 (zh) 曲格列汀的固态形式及其制备方法和用途
CA2927661A1 (en) Solid forms of ivacaftor and processes for the preparation thereof
CN110959002A (zh) 脂化肽的水溶性盐、其制备方法及用途
CN102282125A (zh) 新方法和纯的多晶型物
TWI865508B (zh) Hbv核心蛋白別構調節劑化合物之固體型式
HK40025156A (en) Water soluble salts of lipidated peptides and methods for preparing and using the same
CN104974221A (zh) 二肽及三肽类蛋白酶体抑制剂及其制法和药物用途
EP2397458A1 (en) Organic salts and co-crystals of phenylbutyric acid
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
JPS63233961A (ja) 新規なグルタミン酸誘導体及びそれらの塩類、それらの製造法、薬剤としての使用並びにそれらを含有する組成物
JP5530369B2 (ja) 新規な結晶形
CN102197034A (zh) 舒尼替尼的新型多晶型物及其制备方法
CN101906069A (zh) (s)-2-取代-(3’-乙酰基-2’-吡啶酮-1’-基)乙酸及其制备方法和应用
US11440908B2 (en) Crystalline forms of dasatinib
JP7517705B2 (ja) フロピリミジン化合物の塩および結晶形ならびにその医薬用途
HK40062278A (en) Crystalline forms of (s)-2-(7-cyano-1h-benzimidazol-1 yl)- n-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide
CN116763768A (zh) 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
WO2024243841A1 (zh) 一种病毒蛋白酶抑制剂的结晶及用途
JP2025186242A (ja) ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体
KR20250139359A (ko) 인터류킨-23 수용체의 결정질 펩티드 억제제의 제조 방법
US20220089550A1 (en) Crystalline forms of (s)-2-(7-cyano-1h-benzimidazol-1 yl)-n-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide
JP2023524622A (ja) ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40025156

Country of ref document: HK